Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSO in Crohn's Disease
NCT01576471Phase 2Completed
- Sponsor
- Fortress Biotech
- Start
- Jul 2012
- Primary completion
- Oct 2013
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing TSO 7500 with Placebo (2 arms). Primary endpoint: Induction of Response in Crohn's Disease Activity Index at 12 weeks. Started Jul 2012; status: completed.
02
Drugs
trichuris suis ova
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01576471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576471.